Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Novo Nordisk AS's share price for the quarter that ended in Mar. 2026 was MXN680.5. Novo Nordisk AS's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 4,438 Mil. Therefore, Novo Nordisk AS's market cap for the quarter that ended in Mar. 2026 was MXN3,019,815 Mil.
Novo Nordisk AS's quarterly market cap
declined
from Sep. 2025 (MXN4,665,653 Mil) to Dec. 2025 (MXN4,167,939 Mil) and
declined
from Dec. 2025 (MXN4,167,939 Mil) to Mar. 2026 (MXN3,019,815 Mil).
Novo Nordisk AS's annual market cap
declined
from Dec. 2023 (MXN7,773,025 Mil) to Dec. 2024 (MXN7,417,038 Mil) and
declined
from Dec. 2024 (MXN7,417,038 Mil) to Dec. 2025 (MXN4,167,939 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Novo Nordisk AS's Enterprise Value for Today is MXN3,948,897 Mil.
Novo Nordisk AS (MEX:NOVOBN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Novo Nordisk AS Market Cap Related Terms
Novo Nordisk AS Market Cap Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Novo Nordisk AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a Market Cap of MXN3,617,620 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #8 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Novo Nordisk AS's Market Cap too high?
Novo Nordisk AS's current Market Cap is MXN3,617,620 Mil. Based on the distribution chart, Novo Nordisk AS ranks #8 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #8 out of 1023 companies for Market Cap. This places Novo Nordisk AS in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 207.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 207.38, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Market Cap is 207.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Market Cap is MXN3,617,620 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Market Cap is MXN3,617,620 Mil. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Market Cap is MXN3,617,620 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Market Cap: MXN3,617,620 Mil
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
